BACKGROUND: Promoter methylation of tumor suppressor genes is a frequent and early event in breast carcinogenesis. Paired tumor tissue and serum samples from women with breast cancer show that promoter methylation is detectable in both sample types, with good concordance. This suggests the potential for these serum markers to be used for breast cancer detection. METHODS: The current study was a case-control study nested within the prospective New York University Women's Health Study cohort aimed to assess the ability of promoter methylation in serum to detect pre-clinical disease. Cases were women with blood samples collected within the 6 months preceding breast cancer diagnosis (n=50). Each case was matched to 2 healthy cancer-free controls and 1 cancer-free control with a history of benign breast disease (BBD). RESULTS: Promoter methylation analysis of four cancer-related genes: -RASSF1A, GSTP1, APC and RARβ2, - was conducted using quantitative methylation-specific PCR. Results showed that the frequency of methylation was lower than expected among cases and higher than expected among controls. Methylation was detected in the promoter region of: RASSF1A in 22.0%, 22.9% and 17.2% of cases, BBD controls and healthy controls respectively; GSTP1 in 4%, 10.4% and 7.1% respectively; APC in 2.0%, 4.4% and 4.2% respectively and RARβ2 in 6.7%, 2.3% and 1.1% respectively. CONCLUSION: Methylation status of the four genes included in this study was unable to distinguish between cases and either control group. This study highlights some methodological issues to be addressed in planning prospective studies to evaluate methylation markers as diagnostic biomarkers.
BACKGROUND: Promoter methylation of tumor suppressor genes is a frequent and early event in breast carcinogenesis. Paired tumor tissue and serum samples from women with breast cancer show that promoter methylation is detectable in both sample types, with good concordance. This suggests the potential for these serum markers to be used for breast cancer detection. METHODS: The current study was a case-control study nested within the prospective New York University Women's Health Study cohort aimed to assess the ability of promoter methylation in serum to detect pre-clinical disease. Cases were women with blood samples collected within the 6 months preceding breast cancer diagnosis (n=50). Each case was matched to 2 healthy cancer-free controls and 1 cancer-free control with a history of benign breast disease (BBD). RESULTS: Promoter methylation analysis of four cancer-related genes: -RASSF1A, GSTP1, APC and RARβ2, - was conducted using quantitative methylation-specific PCR. Results showed that the frequency of methylation was lower than expected among cases and higher than expected among controls. Methylation was detected in the promoter region of: RASSF1A in 22.0%, 22.9% and 17.2% of cases, BBD controls and healthy controls respectively; GSTP1 in 4%, 10.4% and 7.1% respectively; APC in 2.0%, 4.4% and 4.2% respectively and RARβ2 in 6.7%, 2.3% and 1.1% respectively. CONCLUSION: Methylation status of the four genes included in this study was unable to distinguish between cases and either control group. This study highlights some methodological issues to be addressed in planning prospective studies to evaluate methylation markers as diagnostic biomarkers.
Authors: Mario F Fraga; Esteban Ballestar; Maria F Paz; Santiago Ropero; Fernando Setien; Maria L Ballestar; Damia Heine-Suñer; Juan C Cigudosa; Miguel Urioste; Javier Benitez; Manuel Boix-Chornet; Abel Sanchez-Aguilera; Charlotte Ling; Emma Carlsson; Pernille Poulsen; Allan Vaag; Zarko Stephan; Tim D Spector; Yue-Zhong Wu; Christoph Plass; Manel Esteller Journal: Proc Natl Acad Sci U S A Date: 2005-07-11 Impact factor: 11.205
Authors: Viola Schmiemann; Alfred Böcking; Marietta Kazimirek; Alexandre Sherlley Casimiro Onofre; Helmut Erich Gabbert; Rainer Kappes; Claus Dieter Gerharz; Hans Juergen Grote Journal: Clin Cancer Res Date: 2005-11-01 Impact factor: 12.531
Authors: Masaru Shinozaki; Dave S B Hoon; Armando E Giuliano; Nora M Hansen; He-Jing Wang; Roderick Turner; Bret Taback Journal: Clin Cancer Res Date: 2005-03-15 Impact factor: 12.531
Authors: Cheryl M Lewis; Leslie R Cler; Da-Wei Bu; Sabine Zöchbauer-Müller; Sara Milchgrub; Elizabeth Z Naftalis; A Marilyn Leitch; John D Minna; David M Euhus Journal: Clin Cancer Res Date: 2005-01-01 Impact factor: 12.531
Authors: Wendie A Berg; Lorena Gutierrez; Moriel S NessAiver; W Bradford Carter; Mythreyi Bhargavan; Rebecca S Lewis; Olga B Ioffe Journal: Radiology Date: 2004-10-14 Impact factor: 11.105
Authors: Xinran Xu; Marilie D Gammon; Hector Hernandez-Vargas; Zdenko Herceg; James G Wetmur; Susan L Teitelbaum; Patrick T Bradshaw; Alfred I Neugut; Regina M Santella; Jia Chen Journal: FASEB J Date: 2012-02-27 Impact factor: 5.191
Authors: Bradley M Downs; Claudia Mercado-Rodriguez; Ashley Cimino-Mathews; Chuang Chen; Jing-Ping Yuan; Eunice Van Den Berg; Leslie M Cope; Fernando Schmitt; Gary M Tse; Syed Z Ali; Danielle Meir-Levi; Rupali Sood; Juanjuan Li; Andrea L Richardson; Marina B Mosunjac; Monica Rizzo; Suzana Tulac; Kriszten J Kocmond; Timothy de Guzman; Edwin W Lai; Brian Rhees; Michael Bates; Antonio C Wolff; Edward Gabrielson; Susan C Harvey; Christopher B Umbricht; Kala Visvanathan; Mary Jo Fackler; Saraswati Sukumar Journal: Clin Cancer Res Date: 2019-07-12 Impact factor: 12.531
Authors: Susan R Sturgeon; Raji Balasubramanian; Catherine Schairer; Hyman B Muss; Regina G Ziegler; Kathleen F Arcaro Journal: Epigenetics Date: 2012-09-17 Impact factor: 4.528
Authors: Vera Kloten; Birte Becker; Kirsten Winner; Michael G Schrauder; Peter A Fasching; Tobias Anzeneder; Jürgen Veeck; Arndt Hartmann; Ruth Knüchel; Edgar Dahl Journal: Breast Cancer Res Date: 2013-01-15 Impact factor: 6.466
Authors: Jane W Y Ng; Laura M Barrett; Andrew Wong; Diana Kuh; George Davey Smith; Caroline L Relton Journal: Genome Biol Date: 2012-06-29 Impact factor: 13.583